KidneyIntelX™ Enables Monitoring of SGLT2 Inhibitor Therapy Response and Corresponding Risk Reduction Over Time

NEXT STORY
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
PREV STORY
Kymera Therapeutics Announces Positive Interim Results from Single Ascending Dose Phase 1 Trial of KT-474 Demonstrating Degrader Proof-of-Mechanism
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Biocartis Group NV: Invitation to annual shareholders meeting

   PRESS RELEASE: REGULATED INFORMATION 11 April 2017, 07:00 CEST                ...

author_avatar
NASDAQ Market News

Aduro Biotech to Present at the 28th Annual Oppenheimer Healthcare Conference

BERKELEY, Calif., March 14, 2018 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced ...

author_avatar
NASDAQ Market News

HTG Molecular Appoints Dr. Joseph Sparano as Lead of Its Clinical Scientific Advisory Board for Breast Cancer Program

TUCSON, Ariz., Jan. 23, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) ...

author_avatar
NASDAQ Market News